We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.00 | 3.23% | 480.00 | 460.00 | 480.00 | 470.00 | 465.00 | 465.00 | 33,518 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 49.95 | 222.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2016 18:49 | So: optimistically..... glass half full? | eeza | |
08/3/2016 17:47 | This will break your pattern, Piedro, and transform you from a pessimist to an optimist...perhaps :-) apad | apad | |
08/3/2016 16:47 | "I would be more than happy if/when TSTL’s managers exercise these change-of-control options for a very fat profit." Don't be fooled!! A buyout would need to be with the approval of the board and usually works in the following manner ... ... 15% premium to the share price + board seats in the new company It has happened to me 3 times - HMY, VDN and AND and not a very pleasant experience as so much research goes to waste. In all 3 cases the Company was looking for a helping hand to leap into the future. I also suspect that Mr. Soler + buddies would prefer marriage with a bigger company than getting in another 'Samler'. AIMHO, BWDIK. | piedro | |
04/3/2016 16:56 | Haven't been able to find any IC comment? apad | apad | |
04/3/2016 11:28 | I don't think he would be buying little chunks in dribs and drabs if he was intending to take the company private as his actions (plus the orchestrated director buying we saw a few days ago) has the effect of boosting the share price. He either sees the shares as cheap or he is trying to create a floor for the share price, I suspect a bit of both. | nehpets81 | |
02/3/2016 18:57 | As mentioned before I think that in view of the immense costs of USA market presence and FDA approval this company with its unique product offering would be best placed under the shelter of a bigger health care co. In which case it would make sense if as ceo you owned as much stock as possible. Obviously to comply with the law he cannot know of any likely bidder but when and if he does it will be too late to buy more stock. On the the other hand as Hyrus says he might just think they are cheap. An agreed take out with a 40% premium to the last option vesting price would make a price of 187p. Just a fairy story for now. | bolador | |
02/3/2016 18:40 | I think he believes it's cheap is all. | hydrus | |
02/3/2016 17:46 | It's a bit volatile at the moment - today was good volatility ! (Didn't realise chairman owned so many) | davr0s | |
02/3/2016 17:13 | ...chairman again. What's he up to? He already has more than a quarter of the company, if he keeps buying perhaps he intends to take it private?? Or, perhaps he just thinks cheap SP, so why not. | naos | |
02/3/2016 11:15 | And another director buy. | pyglet | |
02/3/2016 01:03 | juuunx2, Is it not a dirty word? | piedro | |
01/3/2016 19:21 | Piedro isn't that two words? | juuunx2 | |
01/3/2016 14:12 | I think one need's to focus on the EPS without share based payments going forward and I share the managements optimisim . The SBP's are a on off in this half. As the trigger point was 134p and alreday accrued I agree with PP there is scope back to 130p. Definitely a stong hold for the future prospects long term. Happy to go to sleep on this one. | zipstuck | |
01/3/2016 08:22 | Piedro Have you ever a good word to say for Tristel? | murray80 | |
29/2/2016 22:13 | "There's no doubt they have dropped a big clanger with a badly designed share options scheme" ... dropping 'clangers' - could the MediChem deal be put in that class? - they all seem good ideas at the time. | piedro | |
29/2/2016 21:05 | Another update from Paul Scott (turning more positive)... Regards, Source. +++++++++++++ Tristel (LON:TSTL) Share price: 108.75p (up 4.6% today) No. shares: 42.2m Market cap: £45.9m (at the time of writing, I hold a long position in this share) Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel? I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good". The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy. Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years. Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit. Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise. TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while. | source | |
29/2/2016 07:43 | Another buy by the chairman. Big one this time. Regards,Source. | source | |
27/2/2016 16:51 | As I predicted on results day Investors Chronicle rates as a buy for long term growth prospects | juuunx2 | |
26/2/2016 15:56 | That Chinese hospital looks amazing!Regards,Sour | source | |
26/2/2016 15:32 | Piedro :-) it's the weekend | juuunx2 | |
26/2/2016 15:01 | juuunx2 "if you don't like the stock xxxxoff and moan somewhere else" :-( | piedro | |
26/2/2016 15:00 | juuunx2 "if you don't like the stock xxxxoff and moan somewhere else" :-( | piedro | |
26/2/2016 15:00 | juuunx2 "if you don't like the stock xxxxoff and moan somewhere else" :-( | piedro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions